Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation
I discussed the roles of the three dietary components of Metabolic Engineering (i.e., Zone diet, omega-3 fatty acids, and polyphenols) in increasing AMPK activity in two of my most recent books, The Mediterranean Zone and The Resolution Zone (4,5)
Specifically, significantly elevated levels of proinflammatory cytokines, including TNF-, IL-1, and IFN-
as Januvia) Vildagliptin [7] (EU approved in 2007, and marketed in the EU by Novartis as Galvus) Saxagliptin (FDA approved in 2009, and marketed as Onglyza) Linagliptin (FDA approved in 2011, and marketed as Tradjenta by Eli Lilly and Company and Boehringer Ingelheim) [8] Gemigliptin (approved in Korea in 2012, and marketed by LG Life Sciences as Zemiglo, among other names) [9] Anagliptin (approved in Japan as Suiny in 2012
Prevent muscle loss during dieting*
Recent data that provide deeper insight into ABMR physiopathology suggest that adsorption of DSAs within the allograft cannot entirely explain the occurrence of ABMR in circulating DSA-negative patients (8, 9)
